GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00198279 | Thyroid | PTC | stem cell population maintenance | 61/5968 | 131/18723 | 3.01e-04 | 2.12e-03 | 61 |
GO:00427723 | Thyroid | PTC | DNA damage response, signal transduction resulting in transcription | 12/5968 | 17/18723 | 1.20e-03 | 6.89e-03 | 12 |
GO:004560015 | Thyroid | PTC | positive regulation of fat cell differentiation | 33/5968 | 66/18723 | 1.63e-03 | 9.01e-03 | 33 |
GO:19022306 | Thyroid | PTC | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 17/5968 | 29/18723 | 2.65e-03 | 1.35e-02 | 17 |
GO:00069783 | Thyroid | PTC | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 11/5968 | 16/18723 | 2.70e-03 | 1.36e-02 | 11 |
GO:190216520 | Thyroid | PTC | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 11/5968 | 16/18723 | 2.70e-03 | 1.36e-02 | 11 |
GO:004351617 | Thyroid | PTC | regulation of DNA damage response, signal transduction by p53 class mediator | 19/5968 | 34/18723 | 3.21e-03 | 1.57e-02 | 19 |
GO:19022546 | Thyroid | PTC | negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 13/5968 | 21/18723 | 4.41e-03 | 2.08e-02 | 13 |
GO:004559814 | Thyroid | PTC | regulation of fat cell differentiation | 59/5968 | 139/18723 | 5.50e-03 | 2.50e-02 | 59 |
GO:00063835 | Thyroid | PTC | transcription by RNA polymerase III | 23/5968 | 46/18723 | 7.89e-03 | 3.33e-02 | 23 |
GO:19021666 | Thyroid | PTC | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 9/5968 | 14/18723 | 1.27e-02 | 4.92e-02 | 9 |
GO:000838034 | Thyroid | ATC | RNA splicing | 270/6293 | 434/18723 | 7.50e-35 | 1.19e-31 | 270 |
GO:000218135 | Thyroid | ATC | cytoplasmic translation | 121/6293 | 148/18723 | 1.41e-33 | 1.49e-30 | 121 |
GO:200123335 | Thyroid | ATC | regulation of apoptotic signaling pathway | 206/6293 | 356/18723 | 2.81e-21 | 5.92e-19 | 206 |
GO:000640326 | Thyroid | ATC | RNA localization | 132/6293 | 201/18723 | 1.13e-20 | 1.93e-18 | 132 |
GO:009719335 | Thyroid | ATC | intrinsic apoptotic signaling pathway | 171/6293 | 288/18723 | 1.86e-19 | 2.67e-17 | 171 |
GO:004348435 | Thyroid | ATC | regulation of RNA splicing | 100/6293 | 148/18723 | 2.75e-17 | 2.72e-15 | 100 |
GO:200124233 | Thyroid | ATC | regulation of intrinsic apoptotic signaling pathway | 103/6293 | 164/18723 | 1.67e-14 | 9.77e-13 | 103 |
GO:000641735 | Thyroid | ATC | regulation of translation | 236/6293 | 468/18723 | 2.39e-14 | 1.34e-12 | 236 |
GO:007233135 | Thyroid | ATC | signal transduction by p53 class mediator | 102/6293 | 163/18723 | 3.16e-14 | 1.75e-12 | 102 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF3 | SNV | Missense_Mutation | | c.116N>G | p.Ala39Gly | p.A39G | P17036 | protein_coding | tolerated(0.06) | benign(0.116) | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ZNF3 | insertion | In_Frame_Ins | novel | c.1181_1182insTGCTGTTTTGTTTCATGATTTCGTTAATTATGGAAATTT | p.Asn394_Pro395insAlaValLeuPheHisAspPheValAsnTyrGlyAsnPhe | p.N394_P395insAVLFHDFVNYGNF | P17036 | protein_coding | | | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
ZNF3 | insertion | Frame_Shift_Ins | novel | c.275_276insAACTTCAGACC | p.Glu93ThrfsTer48 | p.E93Tfs*48 | P17036 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ZNF3 | insertion | In_Frame_Ins | novel | c.273_274insGAATGTAGCAAGAGCTTTAAT | p.Asp91_Arg92insGluCysSerLysSerPheAsn | p.D91_R92insECSKSFN | P17036 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ZNF3 | SNV | Missense_Mutation | | c.481G>A | p.Glu161Lys | p.E161K | P17036 | protein_coding | tolerated(0.62) | benign(0.13) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF3 | SNV | Missense_Mutation | rs199648870 | c.632N>A | p.Arg211Gln | p.R211Q | P17036 | protein_coding | tolerated(0.92) | benign(0.109) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF3 | SNV | Missense_Mutation | novel | c.496C>T | p.Pro166Ser | p.P166S | P17036 | protein_coding | tolerated(0.2) | benign(0.081) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF3 | SNV | Missense_Mutation | | c.1247G>T | p.Arg416Ile | p.R416I | P17036 | protein_coding | deleterious(0) | benign(0.31) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF3 | SNV | Missense_Mutation | novel | c.180C>A | p.Phe60Leu | p.F60L | P17036 | protein_coding | tolerated(0.43) | benign(0.019) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ZNF3 | SNV | Missense_Mutation | novel | c.1237C>T | p.Arg413Cys | p.R413C | P17036 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |